Term ends Apr 5, 2027 · Medium confidence
20-year base term ends Apr 5, 2027
Why Medium: A parent in the chain could not be resolved.
Apr 5, 2007
Apr 5, 2027
Nov 14, 2023
This patent's term runs 328 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. No maintenance fee can end this term early. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 5, 2007, when application 11/784,094, the earliest non-provisional in its chain, was filed (this one was filed Feb 7, 2020); a parent in its chain could not be resolved (the next row) | Apr 5, 2027 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +328 days, USPTO patent term adjustment record | Feb 27, 2028 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,253,094, US 10,329,357, US 10,597,452, US 10,604,569, US 11,136,389, US 7,973,142, US 8,524,235, US 8,999,325, US 9,926,367) | capped to Apr 5, 2027 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No maintenance fee can end the term early | In force | High confidence |
| Computed term end | The steps above, in order | Apr 5, 2027 | Medium confidence |
This family
| US 7,973,142 | In force Jun 2029 | Jun 2029 |
| US 8,524,235 | In force May 2027 | May 2027 |
| Application 13/958,990 | Abandoned not computed | not computed |
| US 9,926,367 | In force Apr 2027 | Apr 2027 |
| Application 15/894,442 | Abandoned not computed | not computed |
| US 11,814,425 | this patent Apr 2027 | Apr 2027 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 18, 2020 Reel 53817, frame 543 | Rotello, Rocco Jamie; Peters, Kevin Gene; Davis, Michael Glenn | Aerpio Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Sep 9, 2021 Reel 57448, frame 33 | Aerpio Pharmaceuticals, Inc. | Eyepoint Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 26, 2026 Reel 74489, frame 618 | Eyepoint Pharmaceuticals, Inc. | Eyepoint, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,253,094, US 10,329,357, US 10,597,452, US 10,604,569, US 11,136,389, US 7,973,142, US 8,524,235, US 8,999,325, US 9,926,367.